Abstract
Traditionally, many invasive fungal infections were associated with a poor prognosis, because effective therapeutic options were limited. The recent development of new antifungal agents has significantly contributed to the successful treatment of fungal diseases. These drugs offer novel mechanisms of action and expanded spectrums of activity over traditional treatment options. However, with these new agents comes the need for increased awareness of the potential interactions and toxicities associated with these drugs. Therefore, an understanding of the pharmacokinetic and pharmacodynamic properties of the classes of antifungal compounds is vital for the effective management of invasive fungal infections. This review provides a summary of the pharmacologic principles involved in treatment of fungal diseases.
| Original language | English |
|---|---|
| Pages (from-to) | S28-S39 |
| Journal | Clinical Infectious Diseases |
| Volume | 43 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - Aug 1 2006 |
Funding
Financial support. This article was supported by an educational grant from Schering-Plough.
| Funders |
|---|
| Schering Plough Co |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Pharmacology of systemic antifungal agents'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver